Ningbo University
Ningbo, Zhejiang, 315000, China
NCT Number: NCT07415070
This cluster non-randomized controlled trial aims to evaluate the effectiveness and feasibility of a risk score-guided targeted cervical length screening strategy for the prevention of spontaneous preterm birth in routine community-based prenatal care. Pregnant women are first assessed using a simple preterm birth risk scoring system, and those identified as high risk undergo transvaginal cervical length screening followed by guideline-based preventive interventions when clinically indicated.
The primary objective of the study is to compare this targeted screening strategy with usual prenatal care in reducing the incidence of spontaneous preterm birth occurring between 28 and 36 completed weeks of gestation. Secondary objectives include evaluating the cervical length screening rate, adherence to cervical length screening recommendations, and selected maternal and neonatal outcomes.
Researchers will compare outcomes between women receiving risk score-guided targeted screening and those receiving routine prenatal care without use of the risk scoring system. All participants will be followed until delivery.
Trial opening soon.
Get Notified18 year and older
Female
Interventional
Not applicable
Ningbo, Zhejiang, 315000, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
<!-- -->
Exclusion criteria
Assessment using the validated preterm birth risk scoring system in early pregnancy to stratify women into risk categories.
Women identified as high risk by the preterm birth risk scoring system will undergo transvaginal ultrasound measurement of cervical length during the mid-trimester (16-24 weeks of gestation).
Administration of vaginal progesterone for women with cervical length ≤25 mm, according to guideline-based management.
Placement of cervical cerclage for women meeting established clinical guideline criteria.
Time frame: At delivery.
Proportion of enrolled pregnant women who deliver between 28 and 36 +6 weeks of gestation, based on pregnancy outcome records. The rate of preterm birth will be compared between the intervention group and the control group based on pregnancy outcome records.
Time frame: At delivery.
Proportion of spontaneous preterm births occurring before 28 weeks of gestation.
Time frame: At delivery.
Proportion of spontaneous preterm births occurring between 28 and 31+6 weeks of gestation.
Time frame: At delivery.
Proportion of spontaneous preterm births occurring between 32 and 36+6 weeks of gestation.
Time frame: At mid-trimester (16-24 gestational weeks).
Proportion of all enrolled pregnant women who undergo transvaginal cervical length screening as recommended by the study protocol.
Time frame: At mid-trimester (16-24 gestational weeks).
Proportion of women classified as high risk by the preterm birth risk score who undergo transvaginal cervical length measurement as recommended.
Time frame: Up to 42 weeks of gestation.
Proportion of pregnant women with a cervical length ≤25mm who received guideline-recommended preventive interventions (e.g., vagina progesterone, or other standardized management).
Time frame: At birth.
Birth weight of the newborn, obtained from delivery records and recorded in grams.
Time frame: Within the first 28 days of life (neonatal period).
Admission of the newborn to the neonatal intensive care unit following delivery.
Ningbo University
Other
Effectiveness of Targeted Cervical Length Screening Guided by a Preterm Birth Risk Scoring System in Reducing the Rate of Preterm Birth: a Cluster Non-randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07709663
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
View Trial DetailsNCT07698483
Activity Restriction, Bed Rest
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07699978
Female Urogenital Diseases and Pregnancy Complications, Inflammation
View Trial DetailsNCT07553286
Female Urogenital Diseases and Pregnancy Complications, Gingival Diseases
View Trial Details